Aims
Introduction
The vascular endothelium plays a pivotal role in the pathogenesis of atherosclerosis and its clinical manifestations coronary artery disease (CAD), myocardial infarction, heart failure, stroke, and peripheral artery disease. On the cellular level, endothelial dysfunction and consecutive atherosclerosis are based on a progressive loss of endothelial cells (ECs). Extended EC damage and apoptosis due to classical cardiovascular risk factors result in the loss of the endothelium's integrity. The consequences are an increased vascular permeability of the endothelium followed by facilitated migration of inflammatory cells, and proliferation of vascular smooth muscle cells, resulting in the manifestation of an atherosclerotic lesion. 1 Cell apoptosis is commonly associated with conformational changes of the plasma membrane, condensation of the nucleus, followed by DNA fragmentation, and the release of small (submicroscopic) membranous particles, the so-called microparticles (MPs). 2 Microparticles are directly shed from circulating cells (erythrocytes, leucocytes, platelets) and ECs upon stimulation by activating agents or apoptosis-inducing factors. 3, 4 Microparticles bear phospholipids (e.g. the negatively charged phosphatidylserine which binds to annexin V) and membrane proteins of their mother cell (e.g. CD144 and CD146 for ECs, CD31 for ECs and a proportion of platelets, CD42 and CD61 for platelets, CD45 for leucocytes) allowing partial differentiation between MPs. 5, 6 Recent evidence suggests that MPs are abundantly released in patients with cardiovascular diseases. In case of atherosclerosis-the predominant pathology in cardiovascular disease-MPs derived from endothelial and inflammatory cells as well as platelets are increased. 4,5,7 -19 Experimental and clinical studies suggest that endothelial dysfunction as an independent predictor of adverse events in CAD patients 20, 21 can be assessed quantitatively by measurement of CD31 + /annexin V + MP plasma levels. 22, 23 We hypothesized that CD31 + /annexin V + MPs may contribute to risk stratification in CAD patients by adding information about cardiovascular outcomes beyond that obtained from classical cardiovascular risk factors.
Methods Patients
Between March and November 2003, 200 patients with angiographically proven stable CAD were included in this study. Patients with malignant and inflammatory diseases or severe acute ischaemia other than myocardial ischaemia were excluded from the study. Informed consent was obtained from all patients. The study protocol was approved by the ethics committee of the University of the Saarland. The classification of previous events and follow-up data was made on the basis of medical records and personal interviews. Causes of death were determined by examination of hospital records, autopsy reports, and medical files of the patients' general practitioners. Deaths due to cardiovascular causes included sudden cardiac death and deaths from myocardial infarction, CAD, stroke, or congestive heart failure.
Coronary angiography
Cardiac catheterization was performed according to the guidelines for coronary angiography of the American College of Cardiology and the American Heart Association. 24 Biplane ventriculography was performed in standard projections. The ejection fraction was calculated by dividing the end-diastolic and end-systolic left ventricular areas with the use of an automated computer system (Digital Cardiac Imaging Software, Philips). The extent of CAD was scored, by at least two independent interventional cardiologists, as 0 (stenosis ,50%), 1 (stenosis of any main coronary artery ≥50%), 2 (stenoses of two main coronary arteries ≥50%), and 3 (stenoses of three main coronary arteries ≥50%).
Laboratory methods
Arterial blood was drawn under sterile conditions from the femoral artery before cardiac catheterization and was buffered using sodium citrate. Additional blood samples for routine analyses were obtained. Plasma derived from 10-mL citrate-buffered blood was immediately centrifuged at 13 000 g for 2 min to generate platelet-poor plasma. included as categorical covariate (median MP level). All models were adjusted for gender, hyperlipoproteinaemia, diabetes, number of diseased vessels, chronic kidney disease, concomitant use of angiotensinconverting enzyme-inhibitors (ACE-inhibitors), and statins. We confirmed that the proportionality of hazards assumption was met. Survival was determined with the use of the Kaplan-Meier method. The log-rank test was used to determine statistical differences in terms of survival. To compare the prognostic information provided by a classical risk factor model alone and in combination with the level of CD31 + /annexin V + MPs, associated receiver operating characteristic (ROC) curves for predicted probabilities were generated, and the corresponding areas under the curve along with their 95% CIs were calculated and compared. Statistical significance was assumed when the null hypothesis could be rejected at P , 0.05. Statistical analysis was performed with the use of SPSS Statistics version 17.0.0 (SPSS, Inc., Chicago, IL, USA) and MedCalc version 11.1.1.0 (MedCalc Software, Mariakerke, Belgium).
The investigators initiated the study, had full access to and analysed the data, and wrote the manuscript. All authors vouch for the data and analysis.
Results

Baseline characteristics
A total of 200 patients with stable CAD as diagnosed on coronary angiography were enrolled. Of these, four patients (2%) were lost to follow-up. The average age of the patients was 66.1 + 10.4 years with a high prevalence of cardiovascular risk factors: hypertension (84%), hyperlipoproteinaemia (84%), diabetes (28%), smoking (21%). The number of CD31 + /annexin V + MPs ranged Circulating CD31 + /Annexin V + microparticles from 136 to 11795 events per microlitre platelet-poor plasma (median 2373 events/mL). Levels of CD31 + /annexin V + MPs were analysed after log-transformation (on a base 10 scale) to normalize distribution. The prevalence of diabetes was higher in patients with CD31 + / annexin V + MP levels above the median (37 vs. 19%; P ¼ 0.006).
Concerning other cardiovascular risk factors and clinical variables, no significant differences in baseline characteristics were found according to CD31 + /annexin V + MP levels ( Table 1) .
level in relation to baseline characteristics
By multiple regression analysis that used the log-transformed CD31 + /annexin V + MP level as the dependent variable, the MP level was independently associated with male gender (P ¼ 0.05) and the prevalence of diabetes (P ¼ 0.02) ( Table 2 ). The r 2 value of this multiple regression model was 0.14.
levels and clinical outcomes
The median follow-up time for MACCE-free survival was 6.1 (6.0/6.4) years. A total of 29 patients died (15%), 14 from cardiovascular causes (7%); other causes included sepsis (6/29), pneumonia (4/29), and cancer (5/29). A first MACCE occurred in 72 (37%) patients after a mean follow-up of 2.1 + 2.0 years.
Patients with CD31
+ /annexin V + MP levels above the median (2373 events/mL) had significantly more cardiovascular events (P ¼ 0.001) than patients with lower levels (Table 3, Figure 1 ). In particular, cardiovascular mortality (10 vs. 4%; P ¼ 0.05) and the need for revascularization (35 vs however not identical, population of MPs. Interestingly, binding of platelet MPs with fibrinogen is also involved in thrombus formation in vitro suggesting an additional role in the process of atherosclerosis and, thus, might contribute to risk stratification in CAD patients by reflecting the procoagulatory potential of the individual. 11, 12, 17, 18 Future studies will need to address the role of different MP subtypes on prognosis in patients with CAD. Recent data support the hypothesis that MPs contribute to vascular homoeostasis and the pathogenesis of cardiovascular diseases, including inflammation and vascular dysfunction, in addition to their well-known action on the coagulation process. 5, 33 Such data have led to the concept that MPs are key factors at the crossroads between inflammation, coagulation, and vascular repair. 4, 34 The mechanisms depend on the cellular origin of MPs and may trigger differential consequences on vascular remodeling. The most important impact is probably on alteration of the shear stress-induced response, which is important in the processes leading to atherosclerosis. 34 Increasing evidence suggests that the balance of EC apoptosis and EC regeneration may determine the degree and progression of atherosclerosis. The influence of MPs on endothelial progenitor cell (EPC) migration in vitro suggests a close interaction between EPC and EC apoptosis at the vascular wall. 35 Pirro et al. 28, 30 recently demonstrated that MP release is caused by injured EPC, which are exposed to a pro-apoptotic milieu in the presence of several cardiovascular risk factors. Recently, Zernecke et al.
14
showed that EC-derived apoptotic bodies as paracrine alarm signals in response to tissue damage trigger the microRNA-126 (miR-126)-mediated production of the CXC chemokine CXCL12 and its receptor CXCR4, which counteract apoptosis and recruit progenitor cells. In this study, administration of apoptotic bodies or miR-126 limited atherosclerosis, promoted the incorporation of Sca-1 + progenitor cells, and conferred features of plaque stability in different mouse models of atherosclerosis. Simultaneous assessment of endothelial progenitors and MP subtypes in patients with CAD should unravel potential additive effects on cardiovascular outcome prediction. 36 In conclusion, measurement of circulating MP may serve as a useful tool, allowing us to mirror the actual detrimental effects of cardiovascular risk factors with one integrative marker. Larger studies are needed to further validate this promising cellular biomarker and to elucidate the value of MP measurement for risk stratification in patients with stable CAD. Multivariate analysis included gender, hyperlipoproteinaemia, diabetes, number of diseased vessels, chronic kidney disease, and concomitant use of angiotensin-converting enzyme-inhibitors, and statins. MP, microparticle; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; and MAC(C)E, major adverse cardiovascular (and cerebral) event.
Study limitations
a Cut-off value: 2373 events/mL (median).
Circulating CD31 + /Annexin V + microparticles the development and establishment of clinical routine tests in a larger cohort.
Conclusions
Our results suggest that circulating CD31 + /annexin V + MPs provide information about prognosis and the risk for a future MACCE beyond that obtained from classical cardiovascular risk factors and, thus, might contribute to risk stratification in stable CAD patients.
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Figure 2 Incremental effect of the level of CD31
+ /Annexin V + microparticles in addition to traditional risk factors. Data from a receiver operating characteristic curve analysis concerning a first major adverse cardiovascular and cerebral event. The basic model includes information on age, gender, hypertension, hyperlipoproteinaemia, smoking, diabetes, number of diseased vessels, chronic kidney disease, concomitant use of angiotensin-converting enzyme-inhibitors, beta-blockers, statins, and aspirin. The MP level was treated as log-transformed continuous variable. AUC, area under the curve; CI, confidence interval; and MP, microparticle.
